Leptomeningeal Disease
Leptomeningeal disease (LMD), also known as leptomeningeal metastases or carcinomatosis, is a devastating complication. No reliable epidemiologic data are available, but it is usually agreed that LMD occurs in approximately 10% of patients with cancer.1 LMD has a very poor prognosis with a median overall survival (OS) of weeks without treatment and a modestly improved OS of 3 to 6.3 months despite multiple therapies.2–11 LMD can affect any part of the central nervous system (CNS) axis and can manifest with a wide variety of clinical signs and symptoms.
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Yolanda Pi ña, Dorothee Gramatzki, Peter Forsyth, Eudocia Q. Lee, Emilie Le Rhun Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Epidemiology | Hematology | Neoplastic Meningitis